Nuvo Pennsaid Mid-2006 Filing Planned Following Positive Phase III Results
This article was originally published in The Pink Sheet Daily
Executive Summary
The trial of the topical osteoarthritis therapy was designed to address questions raised in FDA’s August 2002 “not approvable” letter, Nuvo says.
You may also be interested in...
Nuvo’s Pennsaid Resubmission Delayed Again
Firm now projects a potential mid-2009 approval for the topical NSAID for osteoarthritis.
Nuvo’s Pennsaid Resubmission Delayed Again
Firm now projects a potential mid-2009 approval for the topical NSAID for osteoarthritis.
Pennsaid Amended NDA Has Mid-December User Fee Date
Nuvo’s Class 2 resubmission includes data from a Phase III efficacy trial and single-arm, long-term safety study.